Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
BRIDGEWATER, N.J., May 15, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease from the fourth quarter of 2012 and a 43% increase over the first quarter of 2012. For the three-month period ended March 31, 2013, the Company had a net loss of $24.4 million or $0.34 per share, on total revenues of $4.7 million, compared with a net loss of $34.2 million or $0.49 per share, on total revenues of $3.5 million during the same period in 2012. Savient ended the quarter with approximately $68.8 million in cash and short-term investments as compared to $96.3 million in cash and short-term investments as of the prior quarter.
Financial Results of Operations for the Three Months Ended March 31, 2013
Net revenues of the Company increased $1.2 million, or 33%, to $4.7 million for the three-month period ended March 31, 2013, from $3.5 million for the three-month period ended March 31, 2012, primarily driven by the impact of our price increases on KRYSTEXXA. Since the beginning of 2012, we have increased the selling price of KRYSTEXXA by 67% to $3,850 per vial, effective January 16, 2013.
Cost of goods sold increased $1.9 million, or 106%, to $3.6 million for the three-month period ended March 31, 2013, from $1.7 million for the three-month period ended March 31, 2012. The increase is primarily due to a $2.1 million charge to reserve for KRYSTEXXA finished goods and raw material inventory.
Research and development expenses decreased $1.1 million, or 15%, to $6.1 million for the three-month period ended March 31, 2013, from $7.2 million for the three-month period ended March 31, 2012. The decrease is primarily due to lower expenses related to the timing of our U.S. post marketing commitments for KRYSTEXXA coupled with lower compensation costs due to reduced headcount, resulting from our July 2012 reorganization plan.
Selling, general and administrative expenses decreased $9.1 million, or 38%, to $15.2 million for the three-month period ended March 31, 2013, from $24.3 million for the three-month period ended March 31, 2012. The decrease in expense is primarily due to lower marketing, promotion and compensation costs resulting from our July 2012 reorganization plan.
Interest expense on our debt increased $2.5 million, or 55%, to $7.1 million for the three-month period ended March 31, 2013, from $4.6 million for the three-month period ended March 31, 2012, as a result of additional interest due on our 2019 Notes, which were issued on May 9, 2012. Interest expense for the three-month period ended March 31, 2013, primarily reflects $2.7 million of cash interest expense and $4.4 million of non-cash interest expense.
Other income, net of $0.5 million for the three-month period ended March 31, 2013, reflects a non-cash gain of $0.7 million related to the mark-to-market valuation adjustment of our warrant liability.
For the three-month period ended March 31, 2013, we recognized a $2.2 million state income tax benefit as a result of proceeds from the sale of $2.4 million of New Jersey net operating losses through the Technology Business Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority.
For additional information relating to the Company, refer to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, and other filings made with the Securities and Exchange Commission.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at www.savient.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not statements of historical fact should be considered forward-looking statements. We often use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," "would," "could," "should," "target" and similar expressions to identify forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties. For a discussion of some of the risks and important factors that we believe could cause actual results or events to differ from the forward-looking statements that we make, see the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events to differ from those contained in any forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. Any forward-looking statements speak only as of the date of this press release. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
SVNT-I
(Tables to Follow)
| SAVIENT PHARMACEUTICALS, INC. |
||||||||
| March 31, 2013 |
December 31, 2012 |
|||||||
| ASSETS |
||||||||
| Current Assets: |
||||||||
| Cash and cash equivalents |
$ |
36,141 |
$ |
50,332 |
||||
| Short-term investments |
32,648 |
45,949 |
||||||
| Accounts receivable, net |
3,824 |
4,341 |
||||||
| Inventories, net |
2,381 |
4,325 |
||||||
| Prepaid expenses and other current assets |
5,510 |
4,367 |
||||||
| Total current assets |
80,504 |
109,314 |
||||||
| Property and equipment, net |
1,916 |
2,050 |
||||||
| Deferred financing costs, net |
4,740 |
4,969 |
||||||
| Restricted cash and other assets |
2,898 |
2,873 |
||||||
| Total assets |
$ |
90,058 |
$ |
119,206 |
||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT |
||||||||
| Current Liabilities: |
||||||||
| Accounts payable |
$ |
2,509 |
$ |
3,435 |
||||
| Deferred revenues |
299 |
580 |
||||||
| Warrant liability |
2,190 |
2,935 |
||||||
| Accrued interest |
2,978 |
3,150 |
||||||
| Other current liabilities |
14,115 |
21,516 |
||||||
| Total current liabilities |
22,091 |
31,616 |
||||||
| Convertible notes, net of discount of $24,383 at March 31, 2013 |
98,058 |
97,087 |
||||||
| Senior secured notes, net of discount of $41,955 at March 31, 2013 |
128,986 |
125,827 |
||||||
| Other liabilities |
2,908 |
2,973 |
||||||
| Stockholders' Deficit: |
||||||||
| Preferred stock—$.01 par value 4,000,000 shares authorized; no shares issued |
— |
— |
||||||
| Common stock—$.01 par value 150,000,000 shares authorized; 73,871,000 shares |
739 |
731 |
||||||
| Additional paid-in-capital |
398,282 |
397,191 |
||||||
| Accumulated deficit |
(560,361) |
(535,915) |
||||||
| Accumulated other comprehensive loss |
(645) |
(304) |
||||||
| Total stockholders' deficit |
(161,985) |
(138,297) |
||||||
| Total liabilities and stockholders' deficit |
$ |
90,058 |
$ |
119,206 |
||||
| SAVIENT PHARMACEUTICALS, INC. |
||||||||
| Three Months Ended March 31, |
||||||||
| 2013 |
2012 |
|||||||
| Revenues: |
||||||||
| Product sales, net |
$ |
4,692 |
$ |
3,534 |
||||
| Cost and expenses: |
||||||||
| Cost of goods sold |
3,550 |
1,720 |
||||||
| Research and development |
6,134 |
7,246 |
||||||
| Selling, general and administrative |
15,156 |
24,252 |
||||||
| 24,840 |
33,218 |
|||||||
| Operating loss |
(20,148) |
(29,684) |
||||||
| Investment income, net |
33 |
43 |
||||||
| Interest expense on debt |
(7,079) |
(4,557) |
||||||
| Other income, net |
506 |
— |
||||||
| Loss before income taxes |
(26,688) |
(34,198) |
||||||
| Income tax benefit |
2,242 |
— |
||||||
| Net loss |
$ |
(24,446) |
$ |
(34,198) |
||||
| Loss per common share: |
||||||||
| Basic and diluted |
$ |
(0.34) |
$ |
(0.49) |
||||
| Weighted-average number of common and common equivalent shares: |
||||||||
| Basic and diluted |
71,667 |
70,470 |
||||||
| CONTACT: |
|
| Savient Pharmaceuticals, Inc. |
Burns McClellan |
| John P. Hamill |
Caitlyn Murphy |
| Senior Vice President and Chief Financial Officer |
|
| (212) 213-0006 |
|
| (732) 418-9300 |
SOURCE Savient Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article